BioLineRx is trading 6.3% up now at $2.87 amid a broader risk-on session, as softer-than-expected July producer inflation and slightly higher jobless claims strengthened expectations that the Federal Reserve may maintain current rates in September, supporting growth stocks.
- S&P 500 is up 0.71%, while Nasdaq Composite is up 0.96%.
- Investors may also be positioning ahead of the estimated August 13, 2026, second-quarter earnings release.